ArticleFrontiers in immunology2026
A case report of
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Childhood cyclic neutropenia (CN) is a rare hematopoietic disorder. We describe the clinical phenotype, diagnostic features, and management of a pediatric CN case caused by a Methods: We retrospectively analyzed clinical, laboratory, and genetic data from a 7-year-old girl with CN, combined with bioinformatics and literature review to explore genotype-phenotype correlations and optimal therapy. Results: The patient presented with classic 21-day cyclic episodes of fever, oral ulcers, and lymphadenopathy. Peripheral blood absolute neutrophil count (ANC) fell to 0.04×10 Conclusion: Pediatric CN features periodic fever and mucosal infection. Diagnosis requires both cyclic neutropenia documented by serial monitoring and pathogenic ELANE variant confirmation. rhG-CSF remains first-line therapy. Identification of this
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.